Normal view MARC view ISBD view

Adjuvant chemotherapy for osteogenic sarcoma of the extremity with sequential adriamycin and cisplatin

In Journal of Surgical Oncology
By: Pathak AB.
Contributor(s): Desai PB | Deshpande RK | Badhwar R | Pai VR | Nair CN | Kurkure PA | Saikia TK | Nadkarni KS | Gopal R | Pai SK | Iyer RS | Advani SH | .
Material type: materialTypeLabelArticleSeries: Vol 52 Issues 3.Publisher: 1993Description: 181-184.Subject(s): intravenous sequential chemotherapy | cisplatin | adriamycin | chemotherapy | extremities | Osteosarcoma | DDC classification: In: Journal of Surgical OncologySummary: Twenty-nine patients with high-grade nonmetastatic osteogenic sarcoma of the extremities were treated with adjuvant chemotherapy following definitive surgery. Chemotherapy consisted of systemic intravenous Adriamycin and cisplatin in a sequential fashion given for six courses. Nineteen out of 29 patients are alive and continuously disease free over a follow-up period ranging from 9+ to 30+ months. The relapse-free survival was 72%, and overall survival for the entire group was 69%. Median survival is not reached yet. Six out of 29 patients relapsed, of which 1 patient is alive for 6+ months after relapse. Three patients died of chemotherapy toxicity. The results were superior to historical controls treated with surgery alone. The need for more aggressive treatment approaches is discussed
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
(Browse shelf) Available AR11043

Twenty-nine patients with high-grade nonmetastatic osteogenic sarcoma of the extremities were treated with adjuvant chemotherapy following definitive surgery. Chemotherapy consisted of systemic intravenous Adriamycin and cisplatin in a sequential fashion given for six courses. Nineteen out of 29 patients are alive and continuously disease free over a follow-up period ranging from 9+ to 30+ months. The relapse-free survival was 72%, and overall survival for the entire group was 69%. Median survival is not reached yet. Six out of 29 patients relapsed, of which 1 patient is alive for 6+ months after relapse. Three patients died of chemotherapy toxicity. The results were superior to historical controls treated with surgery alone. The need for more aggressive treatment approaches is discussed

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha